EA201591290A3 - Креноланиб для лечения пролиферативных расстройств, связанных с мутацией flt3 - Google Patents

Креноланиб для лечения пролиферативных расстройств, связанных с мутацией flt3

Info

Publication number
EA201591290A3
EA201591290A3 EA201591290A EA201591290A EA201591290A3 EA 201591290 A3 EA201591290 A3 EA 201591290A3 EA 201591290 A EA201591290 A EA 201591290A EA 201591290 A EA201591290 A EA 201591290A EA 201591290 A3 EA201591290 A3 EA 201591290A3
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
proliferative disorders
crenololibs
disorders related
flt3 mutation
Prior art date
Application number
EA201591290A
Other languages
English (en)
Other versions
EA033910B1 (ru
EA201591290A2 (ru
Inventor
Винай К. Джаин
Original Assignee
Эйрог Фармасеутикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51061430&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201591290(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эйрог Фармасеутикалс, Инк. filed Critical Эйрог Фармасеутикалс, Инк.
Publication of EA201591290A2 publication Critical patent/EA201591290A2/ru
Publication of EA201591290A3 publication Critical patent/EA201591290A3/ru
Publication of EA033910B1 publication Critical patent/EA033910B1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y207/00Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001Receptor protein-tyrosine kinase (2.7.10.1)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57426Specifically defined cancers leukemia
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/91Transferases (2.)
    • G01N2333/912Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205Phosphotransferases in general

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Предлагаемое изобретение относится к применению креноланиба в фармацевтически приемлемой форме соли для лечения пролиферативных расстройств с мутацией FLT3, обусловленных конститутивно активированной мутантной FLT3, и к способу лечения теплокровных животных, предпочтительно людей, у которых терапевтически эффективная доза креноланиба вводится животному с вышеупомянутым заболеванием или состоянием.
EA201591290A 2013-01-07 2013-10-14 Применение креноланиба для лечения острого миелоидного лейкоза (омл), связанного с мутацией flt3, и способ лечения EA033910B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361749695P 2013-01-07 2013-01-07
US14/053,011 US9101624B2 (en) 2013-01-07 2013-10-14 Crenolanib for treating FLT3 mutated proliferative disorders
PCT/US2013/064821 WO2014107209A2 (en) 2013-01-07 2013-10-14 Crenolanib for treating flt3 mutated proliferative disorders

Publications (3)

Publication Number Publication Date
EA201591290A2 EA201591290A2 (ru) 2016-03-31
EA201591290A3 true EA201591290A3 (ru) 2016-07-29
EA033910B1 EA033910B1 (ru) 2019-12-09

Family

ID=51061430

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591290A EA033910B1 (ru) 2013-01-07 2013-10-14 Применение креноланиба для лечения острого миелоидного лейкоза (омл), связанного с мутацией flt3, и способ лечения

Country Status (31)

Country Link
US (7) US9101624B2 (ru)
EP (1) EP2941251B1 (ru)
JP (1) JP6288726B2 (ru)
KR (1) KR101885952B1 (ru)
CN (4) CN112138010A (ru)
AP (1) AP2015008628A0 (ru)
AU (1) AU2013371624B2 (ru)
BR (1) BR112015016282A2 (ru)
CA (1) CA2897445C (ru)
CL (1) CL2015001923A1 (ru)
CY (1) CY1120026T1 (ru)
DK (1) DK2941251T3 (ru)
EA (1) EA033910B1 (ru)
ES (1) ES2667958T3 (ru)
HK (1) HK1224211A1 (ru)
HR (1) HRP20180478T1 (ru)
HU (1) HUE038594T2 (ru)
IL (1) IL239802B (ru)
LT (1) LT2941251T (ru)
MX (1) MX369137B (ru)
NO (1) NO3019692T3 (ru)
NZ (1) NZ710720A (ru)
PE (1) PE20151525A1 (ru)
PH (1) PH12015501531B1 (ru)
PL (1) PL2941251T3 (ru)
PT (1) PT2941251T (ru)
RS (1) RS57076B1 (ru)
SG (2) SG11201505327SA (ru)
SI (1) SI2941251T1 (ru)
WO (1) WO2014107209A2 (ru)
ZA (1) ZA201505545B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6407504B2 (ja) 2012-09-21 2018-10-17 アログ・ファーマシューティカルズ・インコーポレイテッドArog Pharmaceuticals,Inc. 恒常的に活性であるリン酸化型flt3キナーゼの阻害方法
BR112015016282A2 (pt) 2013-01-07 2017-07-11 Arog Pharmaceuticals Inc crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
CN109069410B (zh) * 2016-02-26 2022-05-31 安吉奥斯医药品有限公司 用于治疗血液恶性肿瘤和实体瘤的idh1抑制剂
JP7466308B2 (ja) 2016-09-20 2024-04-12 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド Usp10バイオマーカーおよびモジュレーターを用いたamlの同定、評価、予防および処置のための組成物および方法
JP2019532011A (ja) * 2016-11-02 2019-11-07 アログ・ファーマシューティカルズ・インコーポレイテッドArog Pharmaceuticals,Inc. Flt3突然変異増殖性疾患および関連する突然変異を治療するためのクレノラニブ
WO2018118598A1 (en) 2016-12-23 2018-06-28 Arvinas, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
CN114828842A (zh) * 2019-10-21 2022-07-29 理森制药股份公司 用于治疗急性髓系白血病的包含dhodh抑制剂的组合物
US11713310B2 (en) 2020-07-20 2023-08-01 Arog Pharmaceuticals, Inc. Crystal forms of crenolanib and methods of use thereof
US20220047574A1 (en) * 2020-08-15 2022-02-17 Arog Pharmaceuticals, Inc. Crenolanib for treating pdgfr alpha mutated proliferative disorders
WO2022051429A1 (en) 2020-09-02 2022-03-10 Daniel Choi Systems and methods for augmented reality environments and tokens
US11969420B2 (en) 2020-10-30 2024-04-30 Arog Pharmaceuticals, Inc. Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders
JP2023063189A (ja) * 2021-10-22 2023-05-09 アログ・ファーマシューティカルズ・インコーポレイテッド 以前の治療に対して再発性/不応性のflt3突然変異増殖性障害を治療するためのクレノラニブ

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990146A (en) 1997-08-20 1999-11-23 Warner-Lambert Company Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation
WO1999016755A1 (en) 1997-09-26 1999-04-08 Merck & Co., Inc. Novel angiogenesis inhibitors
UA75055C2 (ru) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Производные бензоимидазола, которые применяются как антипролиферативное средство, фармацевтическая композиция на их основании
CA2424689A1 (en) 2000-10-17 2002-04-25 Merck & Co., Inc. Orally active salts with tyrosine kinase activity
AU2363902A (en) * 2000-10-31 2002-05-15 Ciba Sc Holding Ag Crystalline forms of fluvastatin sodium
AR035885A1 (es) 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
US7101884B2 (en) 2001-09-14 2006-09-05 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003024931A1 (en) 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
TWI259081B (en) 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
TWI302836B (en) 2001-10-30 2008-11-11 Novartis Ag Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
WO2003057690A1 (en) 2001-12-27 2003-07-17 Theravance, Inc. Indolinone derivatives useful as protein kinase inhibitors
TW200406374A (en) 2002-05-29 2004-05-01 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
CA2495386C (en) 2002-08-14 2011-06-21 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
EP1539754A4 (en) 2002-08-23 2009-02-25 Novartis Vaccines & Diagnostic BENZIMIDAZOLE QUINOLINONES AND USES THEREOF
PA8580301A1 (es) 2002-08-28 2005-05-24 Pfizer Prod Inc Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
EP1566379A4 (en) 2002-10-29 2005-11-09 Kirin Brewery QUINOLINE AND QUINAZOLINE DERIVATIVES INHIBITING THE AUTOPHOSPHORYLATION OF FLT3 AND MEDICAL COMPOSITIONS CONTAINING SAME
JP2006511616A (ja) 2002-11-13 2006-04-06 カイロン コーポレイション 癌の処置方法およびその関連方法
TWI335913B (en) 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
AU2003297160A1 (en) 2002-12-18 2004-07-22 Vertex Pharmaceuticals Incorporated Benzisoxazole derivatives useful as inhibitors of protein kinases
BRPI0411794A (pt) 2003-06-24 2006-08-08 Pfizer Prod Inc processos para a preparação de derivados de 1-[(benzoimidazol-1-il)quinolin-8-il]piperidin-4-ilamina
AU2006309171A1 (en) * 2005-10-28 2007-05-10 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2012052757A1 (en) * 2010-10-20 2012-04-26 Astrazeneca Ab Tumour phenotype patient selection method
AU2012345666A1 (en) * 2011-11-30 2014-06-19 Cedars-Sinai Medical Center Targeting microRNAs miR-409-5p, miR-379 and miR-154* to treat prostate cancer bone metastasis and drug resistant lung cancer
JP6407504B2 (ja) 2012-09-21 2018-10-17 アログ・ファーマシューティカルズ・インコーポレイテッドArog Pharmaceuticals,Inc. 恒常的に活性であるリン酸化型flt3キナーゼの阻害方法
KR20140040594A (ko) 2012-09-26 2014-04-03 아로그 파마슈티칼스, 엘엘씨 돌연변이체 c-kit의 억제 방법
BR112015016282A2 (pt) 2013-01-07 2017-07-11 Arog Pharmaceuticals Inc crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado

Also Published As

Publication number Publication date
ES2667958T3 (es) 2018-05-16
AU2013371624A1 (en) 2015-08-20
NO3019692T3 (ru) 2018-06-16
HUE038594T2 (hu) 2018-10-29
CN109966292A (zh) 2019-07-05
LT2941251T (lt) 2018-04-10
PH12015501531A1 (en) 2015-09-21
CL2015001923A1 (es) 2016-01-15
US9801870B2 (en) 2017-10-31
PH12015501531B1 (en) 2015-09-21
US20220409610A1 (en) 2022-12-29
HK1224211A1 (zh) 2017-08-18
EP2941251A2 (en) 2015-11-11
IL239802A0 (en) 2015-08-31
EA033910B1 (ru) 2019-12-09
BR112015016282A2 (pt) 2017-07-11
CA2897445C (en) 2019-04-30
JP6288726B2 (ja) 2018-03-07
US20140194464A1 (en) 2014-07-10
US10213423B2 (en) 2019-02-26
US9393240B2 (en) 2016-07-19
KR101885952B1 (ko) 2018-08-06
MX2015008777A (es) 2015-11-13
AP2015008628A0 (en) 2015-08-31
US20150238479A1 (en) 2015-08-27
PL2941251T3 (pl) 2018-07-31
NZ710720A (en) 2020-06-26
CN112138010A (zh) 2020-12-29
CY1120026T1 (el) 2018-12-12
RS57076B1 (sr) 2018-06-29
EP2941251A4 (en) 2016-08-24
JP2016508148A (ja) 2016-03-17
DK2941251T3 (en) 2018-03-26
PE20151525A1 (es) 2015-10-23
US11458131B2 (en) 2022-10-04
AU2013371624B2 (en) 2018-02-08
CN110200970A (zh) 2019-09-06
US20190183879A1 (en) 2019-06-20
US20180015081A1 (en) 2018-01-18
SG11201505327SA (en) 2015-08-28
KR20150141930A (ko) 2015-12-21
HRP20180478T1 (hr) 2018-06-15
US9101624B2 (en) 2015-08-11
SG10201705611PA (en) 2017-08-30
WO2014107209A2 (en) 2014-07-10
SI2941251T1 (en) 2018-06-29
PT2941251T (pt) 2018-03-23
US20200390756A1 (en) 2020-12-17
US20160303109A1 (en) 2016-10-20
CA2897445A1 (en) 2014-07-10
EP2941251B1 (en) 2018-03-07
US11007188B2 (en) 2021-05-18
IL239802B (en) 2020-06-30
MX369137B (es) 2019-10-30
EA201591290A2 (ru) 2016-03-31
ZA201505545B (en) 2016-10-26
CN105555272A (zh) 2016-05-04

Similar Documents

Publication Publication Date Title
EA201591290A3 (ru) Креноланиб для лечения пролиферативных расстройств, связанных с мутацией flt3
EA201690212A8 (ru) Способы лечения или профилактики офтальмологических патологических состояний
EA201691872A1 (ru) Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
MX2016004030A (es) Inhibidores sustituidos de nicotinamida de btk y su preparacion y uso en el tratamiento del cancer, inflamacion y enfermedad autoinmune.
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
MY197558A (en) Methods of treating depression using orexin-2 receptor antagonists
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
MX2021002321A (es) Nuevos metodos.
MX2016009306A (es) Reequilibrado inmunologico epicutaneo.
EA201492102A1 (ru) Антагонисты lingo-2 для лечения заболеваний, в которых участвуют двигательные нейроны
MX2021002322A (es) Nuevos metodos.
EA201691385A1 (ru) Комбинированная терапия рака
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
EA201690974A1 (ru) Гидроморфон и налоксон для лечения боли и индуцированного опиоидами синдрома дисфункции кишечника
EA201790352A1 (ru) Терапевтическое лечение на основе анаморелина
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms
MX2014014817A (es) Compuestos para el tratamiento de inflamacion y dolor.
EA201992414A1 (ru) Комбинация nk1-антагониста и способ лечения синуклеинопатий
AR102494A1 (es) Métodos para tratar enfermedades oculares
PH12016502107A1 (en) Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
EA201990341A1 (ru) Замещенные диазагетеробициклические соединения и их применение
MX2020007183A (es) Inhibidores de ret9 y vegfr2.
EA201992284A1 (ru) Композиции и способы лечения синуклеинопатий
RU2014104644A (ru) Способ повышения эффективности лечения коров, больных острым гнойно-катаральным эндометритом